Roivant Sciences Ltd.

Roivant Sciences director bought 16,666,666 IMVT shares at $21.00 ($350.0M); holdings now 113.32M shares (+17.2%)

A Roivant Sciences director made a substantial $350.0M open-market purchase of 16,666,666 shares at $21.00, expanding holdings by 17.2% to 113.32M shares. The transaction occurred at a 20.5% discount to the current price of $26.42, and the stock has appreciated 63.5% over the past 90 days. However, the insider's cross-ticker track record shows only 50% win rate on prior buys with a -7.9% average 90-day return, and at IMVT specifically, two prior buys on 2025-01-13 and 2023-10-02 produced mixed results: the more recent purchase is down 26.6% at the 90-day mark. IMVT remains unprofitable with net income of $-126,502,000.00 over its most recent fiscal year, and the timing of this outsized accumulation after recent sharp gains warrants scrutiny of whether this reflects conviction or represents a post-run-up acquisition by an affiliated party.

Roivant Sciences director buys 16,845,010 IMVT shares at $20.00 for $336,900,200; holdings surge to 96,650,341 shares (+21.1%)

A Roivant Sciences Ltd. director acquired 16,845,010 shares of Immunovant at $20.00 on 2025-01-13, increasing holdings by 21.1% to 96,650,341 shares total. The transaction represents a $336,900,200 commitment at a price $4.40 below the current market level of $24.40. The director's prior buy at this same ticker on 2023-10-02 achieved a 90-day return of +10.9%, establishing a pattern of well-timed accumulation at Immunovant. However, the company remains unprofitable with a net income of $-109,119,000 over its most recent full fiscal year, and the current share price sits 43.1% below the 52-week high, reflecting significant recent weakness.